live
vaccin
gener
falseposit
result
common
influenza
assay
includ
revers
transcriptasepcr
rtpcr
cultur
antigen
test
threaten
integr
epidemiolog
data
may
misdirect
treatment
control
effort
report
develop
rtpcr
test
distinguish
live
flumist
tm
vaccin
fmv
strain
circul
influenza
strain
clinic
sampl
primer
valid
use
influenzaposit
sampl
unvaccin
patient
packag
fmv
one
pcrposit
asymptomat
vaccin
furthermor
assay
use
experiment
test
lab
collect
influenzaposit
sampl
influenza
season
sever
preseason
isol
determin
rate
vaccinederiv
falseposit
result
differ
epidemiolog
condit
analyt
clinic
valid
show
assay
sensit
specif
experiment
result
demonstr
influenzaposit
sampl
collect
influenza
season
ill
previouslyvaccin
militari
personnel
repres
real
infect
circul
strain
final
assay
show
four
preseason
influenzaposit
sampl
fals
posit
result
vaccin
shed
vaccinediscriminatori
rtpcr
method
describ
provid
first
test
design
distinguish
fmv
strain
circul
strain
result
show
test
effect
demonstr
import
test
age
live
vaccin
publish
elsevi
ltd
fmv
live
attenu
coldadapt
trival
influenza
vaccin
administ
intranas
contain
three
influenza
strain
b
strain
reassort
two
genom
segment
encod
primari
surfac
antigen
hemaggluttinin
h
neuraminidas
n
deriv
antigen
relev
wildtyp
strain
product
gene
confer
abil
induc
protect
immun
current
circul
influenza
taken
isol
recommend
annual
inclus
vaccin
formul
remain
six
genom
segment
deriv
master
donor
viru
mdv
strain
deriv
aann
bann
strain
origin
isol
respect
origin
isol
evolv
serial
passag
sequenti
lower
temperatur
confer
temperaturesensit
coldadapt
attenu
phenotyp
previou
studi
shown
live
vaccin
strain
recov
vaccin
individu
day
postvaccin
could
therefor
yield
fals
influenzaposit
result
rtpcr
test
rapid
antigen
assay
culturebas
diagnost
one
studi
shed
demonstr
vaccin
subject
day
postvaccin
approxim
seven
day
postvaccin
given
studi
popul
militari
recruit
highli
vaccin
sampl
gener
collect
train
within
approxim
week
vaccin
risk
gener
falseposit
influenza
result
due
fmv
shed
signific
use
molecular
diagnost
detect
influenza
becom
widespread
due
low
cost
high
sensit
increas
speed
rel
viral
cultur
naval
health
research
center
nhrc
laboratori
use
rtpcr
princip
diagnost
method
detect
influenza
b
clinic
sampl
univers
influenza
primer
use
nhrc
set
tabl
mani
primer
describ
literatur
target
conserv
region
matrix
gene
incap
discrimin
mdv
current
circul
strain
ensur
influenzaposit
sampl
identifi
routin
influenza
influenza
b
rtpcr
assay
communityacquir
infect
result
shed
recent
vaccin
primer
develop
discrimin
mdv
current
circul
influenza
strain
mutat
accru
mdv
cold
adapt
wide
dispers
allow
distinguish
primer
design
around
fortun
mdv
deriv
strain
origin
collect
year
ago
allow
enough
time
natur
diverg
creat
mani
suitabl
polymorph
region
strainspecif
primer
design
within
hn
subtyp
molecular
evolut
matrix
gene
follow
pattern
serial
replac
new
variant
allel
aris
recent
circul
allel
henc
chang
character
accumul
mutat
drift
time
form
linear
phylogenet
success
evolutionari
pattern
mind
strainspecif
discrimin
primer
design
three
mdv
circul
strain
three
domin
influenza
subtyp
influenza
b
set
primer
exploit
polymorph
aros
specif
subtyp
lineag
isol
relev
vaccin
strain
fig
align
illustr
gener
pattern
influenza
evolut
use
influenza
matrix
gene
fmva
forward
primer
exampl
phylogenet
matrix
gene
influenza
mdv
strain
lie
directli
current
circul
clade
current
strain
close
strain
respect
matrix
gene
pattern
repres
fact
current
matrix
gene
diverg
independ
mdv
sequenc
henc
differ
mdv
differ
way
thu
singl
pair
pcr
test
differenti
entir
spectrum
circul
strain
influenza
fmv
influenza
mdv
fmva
primer
distinguish
influenza
mdv
circul
strain
also
give
posit
result
circul
strain
primer
shown
tabl
vaccin
primer
design
yield
posit
result
current
strain
give
posit
result
mdv
yield
posit
result
circul
strain
henc
definit
identif
influenza
mdv
requir
three
result
posit
fmva
primer
set
neg
result
primer
set
analysi
matrix
present
tabl
clariti
issu
influenza
b
type
current
circul
influenza
bs
distinct
clade
respect
influenza
b
mdv
primer
present
cover
influenza
strain
current
circul
unit
state
world
current
pattern
infect
http
wwwcdcgovflu
hold
true
pathogen
alreadi
identifi
influenza
pair
test
primer
fmva
primer
usual
definit
identifi
strain
communityacquir
give
posit
result
primer
howev
test
yield
neg
result
primer
posit
result
fmva
primer
primer
must
use
determin
strain
vaccin
three
pcr
definit
discrimin
fmv
shed
circul
strain
influenza
case
http
wwwcdcgovflu
final
rare
strain
also
identifi
recent
year
slightli
diverg
primer
site
henc
also
present
primer
design
catch
circul
strain
like
primer
design
surveil
rapidli
evolv
rna
virus
primer
circul
strain
need
replac
strain
continu
evolv
howev
unlik
circul
strain
back
mutat
replac
strain
target
allel
expect
result
differ
primer
set
amplifi
differ
templat
indic
expect
amplif
indic
expect
neg
indic
primer
may
give
either
neg
posit
result
ident
vaccin
strain
henc
improb
vaccin
primer
ever
requir
replac
inclus
primer
pair
vaccin
circul
strain
allow
identif
genet
drift
affect
recognit
one
primer
pair
chang
yield
strain
give
neg
test
result
becom
common
circul
strain
sequenc
primertarget
region
address
possibl
mismatch
primer
initi
test
specif
panel
neg
control
consist
common
respiratori
pathogen
bacteri
viral
except
influenza
common
environment
commens
bacteria
like
escherichia
coli
see
tabl
specif
ident
fmv
fmv
b
posit
control
dilut
seri
nucleic
acid
extract
flumist
tm
vaccin
medimmun
test
evalu
sensit
vaccinespecif
primer
fmva
fmvb
specif
circul
strain
primer
circb
tabl
one
sampl
collect
nasal
swab
one
author
nef
approxim
one
hour
fmv
vaccin
serv
posit
clinic
control
sampl
live
vaccin
strain
clinic
circulatingstrain
control
twelv
unvaccin
patient
throat
swab
ts
sampl
previous
test
posit
influenza
test
new
vaccinediscrimin
primer
set
set
tabl
similarli
influenza
culturepositivertpcrposit
ts
sampl
individu
treat
inactiv
inject
vaccin
also
test
sinc
inject
vaccin
would
expect
yield
influenzaposit
result
cultur
rtpcr
sampl
type
serv
posit
control
sensit
circul
strain
primer
set
well
neg
control
specif
vaccin
primer
set
except
sampl
identifi
expect
crossreact
fmva
primer
circul
influenza
bposit
clinic
control
two
ts
sampl
collect
gener
unvaccin
border
popul
two
sampl
unvaccin
recruit
previous
test
posit
influenza
b
cultureif
rtpcr
test
primer
set
similarli
influenza
b
culturepositivertpcrposit
ts
sampl
recruit
treat
inactiv
inject
vaccin
also
test
tabl
clinic
circulatingstrain
neg
control
seven
ts
sampl
asymptomat
recruit
recent
vaccin
fmv
test
sampl
previous
test
neg
influenza
cultureif
rtpcr
univers
primer
set
tabl
develop
assay
use
test
collect
influenzaposit
clinic
ts
sampl
symptomat
patient
vaccin
fmv
day
month
prior
sampl
collect
sampl
could
origin
test
posit
due
either
vaccin
strain
communityacquir
wildtyp
strain
fortyf
origin
test
posit
influenza
cultureif
andor
rtpcr
ten
test
posit
influenza
b
influenza
sampl
chosen
six
culturenegativertpcrposit
specif
includ
fmv
growthlimit
vaccin
shed
might
expect
gener
type
discrep
result
independ
sequenc
align
influenza
matrix
gene
made
use
clustal
w
algorithm
lasergen
megalign
softwar
dnastar
madison
wi
repres
tempor
divers
select
human
isol
collect
sequenc
found
use
genbank
http
wwwncbinlmnihgov
influenza
sequenc
databas
http
wwwflulanlgov
align
also
includ
matrix
sequenc
fmv
influenza
mdv
kindli
provid
jin
hong
medimmun
inc
gaithersburg
md
vaccinespecif
primer
chosen
would
amplifi
sequenc
mdv
primari
current
circul
subtyp
circul
strain
primer
chosen
subtyp
would
amplifi
sequenc
circul
strain
vaccin
strain
primer
shown
tabl
method
use
design
primer
distinguish
circul
influenza
b
influenza
b
mdv
primer
obtain
integr
dna
technolog
coralvil
ia
rna
extract
fmv
ts
sampl
use
qiaamp
dna
blood
bodi
fluid
kit
qiagen
valencia
ca
follow
manufactur
instruct
rtpcr
perform
use
onestep
rtpcr
kit
qiagen
accord
manufactur
instruct
protocol
use
qsolut
nm
final
primer
concentr
follow
modif
final
reaction
volum
ml
ml
sampl
use
templat
reaction
perform
icycl
pcr
machin
biorad
hercul
ca
cycl
condit
includ
final
extens
final
hold
regard
paramet
reaction
cycl
shown
tabl
pcr
appear
robust
use
anneal
temperatur
suggest
anneal
temperatur
tune
new
reagent
set
sampl
type
thermal
cycl
platform
specif
machin
differ
ramp
rate
rtpcr
analyz
agaros
gel
electrophoresi
ethidium
bromid
visual
clinic
sampl
symptomat
individu
collect
part
nhrc
ongo
respiratori
surveil
effort
ts
sampl
taken
consent
militari
recruit
meet
case
definit
temperatur
respiratori
symptom
swab
place
viral
transport
medium
remel
lenexa
ks
frozen
sent
dri
ice
nhrc
sampl
prealiquot
store
monitor
freezer
sampl
test
nhrc
colleg
american
pathologist
cap
certifi
influenza
b
cultureimmunofluoresc
cultureif
univers
influenza
rtpcr
test
set
tabl
nhrc
influenza
surveil
rtpcr
involv
two
independ
amplif
differ
primer
set
posit
repres
sampl
yield
amplicon
primer
set
influenza
b
identif
initi
achiev
nhrc
either
cultureif
singl
univers
influenza
b
realtim
pcr
set
sampl
individu
receiv
fmv
within
one
week
sampl
collect
previous
test
neg
influenza
cultur
rtpcr
two
influenza
bposit
ts
sampl
collect
symptomat
individu
usmexico
border
popul
low
vaccin
rate
assum
unvaccin
one
nasal
swab
sampl
collect
one
author
nef
receiv
fmv
primer
pair
test
neg
control
panel
repres
potenti
confound
includ
respiratori
bacteria
virus
might
caus
similar
symptom
commens
environment
common
speci
might
incident
present
specimen
obtain
either
american
type
cultur
collect
nhrc
colleg
american
pathologist
cap
certifi
bacteriolog
virolog
lab
test
titer
ml
suspend
distil
water
test
perform
appropri
posit
control
pcr
plate
repres
pcr
result
shown
fig
sensit
fmva
fmvb
primer
set
found
tissu
cultur
infecti
dose
tcid
result
calcul
tcid
fmv
packag
insert
per
ml
dose
fmv
dilut
also
test
neg
four
circul
strain
primer
set
see
tabl
influenza
b
circulatingstrain
control
sampl
four
symptomat
unvaccin
patient
symptomat
patient
vaccin
inject
vaccin
test
neg
fmvb
primer
posit
circb
primer
see
tabl
crossreact
influenza
influenza
b
test
control
sampl
influenza
control
sampl
symptomat
recruit
receiv
fmv
unvaccin
receiv
inject
vaccin
test
neg
fmva
primer
thirtythre
test
posit
primer
remain
sampl
posit
primer
see
tabl
within
sampl
set
specif
fmva
primer
sensit
primer
respect
cultur
immunofluoresc
respect
univers
flua
primer
fmva
primer
gave
posit
result
three
sampl
expect
see
tabl
also
see
introduct
primer
design
explan
tabl
specificityanalysi
matrix
primer
gave
neg
result
control
sampl
fmv
dilut
yield
sensit
specif
sampl
set
primer
could
valid
sensit
access
sampl
test
sampl
expect
crossreact
strongli
strain
fmv
none
six
novel
discriminatori
primer
set
set
tabl
yield
posit
result
test
neg
control
sampl
ident
neg
control
isol
list
tabl
seven
influenza
rtpcrpositivecultureneg
sampl
collect
symptomat
fmvvaccin
recruit
influenza
season
test
posit
one
circul
strain
neg
vaccin
ten
influenza
b
rtpcrpositivecultureposit
sampl
collect
symptomat
fmvvaccin
recruit
test
posit
circul
influenza
b
neg
vaccin
thirti
rtpcrpositivecultureposit
influenza
sampl
collect
symptomat
fmvvaccin
recruit
influenza
season
test
neg
fmva
primer
posit
primer
pool
result
indic
rang
dilut
seri
report
result
obtain
fmv
day
nasal
swab
taken
author
nef
immedi
fmv
vaccin
tabl
summari
influenzaseason
experiment
sampl
appear
contain
communityacquir
influenza
strain
four
rtpcrposit
sampl
collect
symptomat
fmvvaccin
recruit
begin
influenza
season
test
neg
circul
strain
posit
vaccin
fmv
appear
case
falseposit
test
result
relat
vaccin
shed
mani
primer
set
test
crossreact
strain
outsid
scope
design
discriminatori
capac
expect
see
section
tabl
must
reiter
purpos
test
distinguish
fmv
shed
legitim
communityacquir
influenza
infect
determin
subtyp
togeth
result
demonstr
sensit
specif
design
test
result
also
strongli
suggest
use
sampl
collect
influenza
season
capcertifi
influenza
cultur
rtpcr
test
primarili
yield
posit
result
patient
legitim
communityacquir
pathogen
influenza
oppos
fals
posit
result
vaccin
strain
shed
hand
sever
result
work
suggest
gener
rtpcr
method
detect
fmv
henc
reiter
consensu
literatur
live
intranas
vaccin
confound
test
design
identifi
communityacquir
pathogen
support
result
includ
four
sampl
fmvvaccin
recruit
test
posit
vaccin
circul
influenza
strain
posit
result
control
nasal
swab
sampl
author
taken
immedi
fmv
vaccin
importantli
fall
lab
identifi
appear
four
earlyseason
influenza
infect
recruit
train
center
use
primari
rtpcr
method
discoveri
would
epidemiolog
concern
given
time
year
howev
four
sampl
test
posit
fmva
primer
neg
primer
see
tabl
suggest
origin
fluaunivers
posit
result
due
shed
vaccin
strain
suggest
substanti
fact
recruit
vaccin
tabl
neg
control
use
assay
specif
vaccin
discriminatori
primer
shown
speci
strain
test
human
parainfluenza
viru
klebsiella
pneumonia
staphylococcu
aureu
respiratori
syncyti
viru
fmv
within
day
sampl
sampl
yield
cultur
viru
result
show
influenzaposit
rtpcr
result
surveil
vaccin
popul
time
pathogen
influenza
wide
circul
like
falseposit
fmv
strain
shed
strongli
support
epidemiolog
clinic
necess
test
discrimin
vaccin
strain
circul
pathogen
strain
particularli
critic
time
public
health
agenc
increas
offseason
influenza
surveil
effort
protect
public
threat
influenza
pandem
news
report
indic
militari
alon
contract
purchas
million
dose
flumist
influenza
season
baltimor
busi
journal
june
past
two
vaccin
season
medimmun
sold
three
million
dose
drug
worldwid
expect
introduct
refrigeratorst
version
like
increas
sale
increas
public
confid
familiar
flumist
introduc
influenza
season
first
inhal
influenza
vaccin
four
symptomat
influenzaposit
individu
test
posit
circul
vaccin
strain
influenza
receiv
fmv
vaccin
day
prior
sampl
collect
vaccineinduc
immun
influenza
averag
take
day
confer
immun
henc
result
consist
patient
histori
suggest
patient
simultan
infect
communityacquir
influenza
strain
shed
fmv
influenza
interest
note
infect
patient
shed
detect
level
vaccin
strain
none
seven
asymptomat
patient
sampl
within
six
day
fmv
vaccin
gave
posit
result
vaccinespecif
test
individu
among
asymptomat
control
shown
tabl
rais
possibl
vaccin
strain
surviv
andor
replic
support
coinfect
communityacquir
strain
medimmun
inc
current
expand
line
fmv
includ
avian
influenza
mdv
use
effort
use
current
human
influenza
fmv
avian
h
n
gene
segment
take
place
human
influenza
equival
fmv
primer
present
abl
distinguish
vaccin
real
avian
influenza
effect
discrimin
human
influenza
fmv
communityacquir
influenza
